Several analysts have recently updated their ratings and price targets for Mirum Pharmaceuticals (NASDAQ: MIRM):
- 8/29/2026 – Mirum Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
- 8/27/2026 – Mirum Pharmaceuticals was given a new $137.00 price target by UBS Group AG.
- 8/27/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/27/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $137.00 price target on the stock.
- 8/16/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
- 8/8/2026 – Mirum Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
- 8/6/2026 – Mirum Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
- 8/6/2026 – Mirum Pharmaceuticals was given a new $123.00 price target by Robert W. Baird.
- 8/6/2026 – Mirum Pharmaceuticals was given a new $137.00 price target by Morgan Stanley.
- 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $148.00 to $135.00. They now have an “outperform” rating on the stock.
- 8/6/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..
- 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by TD Cowen from $145.00 to $140.00. They now have a “buy” rating on the stock.
- 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by Citizens Jmp from $146.00 to $137.00. They now have a “market outperform” rating on the stock.
- 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by HC Wainwright from $185.00 to $140.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $142.00 to $148.00. They now have an “outperform” rating on the stock.
Insiders Place Their Bets
In other news, SVP Jolanda Howe sold 658 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the completion of the sale, the senior vice president directly owned 616 shares in the company, valued at $61,600. This represents a 51.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 133,814 shares of company stock valued at $13,914,562 in the last 90 days. 8.32% of the stock is owned by insiders.
Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Read More
- Five stocks we like better than Mirum Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Mirum Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
